RxDoctor Payments Data

Benjamin Rudnick, MD

Urology · Trumbull, CTNPI 1316392228

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (49.3%), education and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Intuitive Surgical at 49.5% of the total. Reporting peaked in 2022 at $3,038 and has fallen 98.4% since, to $50 in 2025.

$4,100in general payments, 2019–2025

Across 42 payments — averaging $97.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • Medtronic$936
  • Johnson & Johnson$248
  • Boston Scientific$210
  • Coloplast$159
  • Photocure Inc$133
  • plus $386 from 5 others

What the payments were for

  • Travel & lodging$98024%
  • Food & beverage$2,02149%
  • Education$1,10027%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,100 in reported general payments places this provider in the 65th percentile of 156 urology providers in Connecticut.

See all urology providers in Connecticut

Medicare billing

Part B allowed, 2024
$144,901
Medicare patients
350
Services billed
3,260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron106$114,949
MyrbetriqMirabegron31$33,193
Tamsulosin Hcl393$4,781
Estradiol80$4,563
Finasteride88$1,104
Alfuzosin Hcl ErAlfuzosin Hcl50$885
Methenamine Hippurate14$749
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst56$514
Dutasteride21$491
NitrofurantoinNitrofurantoin Macrocrystal11$476
Solifenacin Succinate15$439
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim73$275
CefuroximeCefuroxime Axetil28$243
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip15$200
Ciprofloxacin Hcl39$188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$100$33,19331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 156 urology providers in Connecticut.

Other urology in Trumbull

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →